Results 21 to 30 of about 323,752 (284)
Frontiers in Immunology, 2022 Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC ...
Antonio Giovanni Solimando +4 more
doaj +1 more source
Role of mTOR signaling in tumor microenvironment. An overview [PDF]
, 2018 The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara +8 more
core +2 more sources
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases
Frontiers in Immunology, 2019 Angiogenesis is facilitated by the proteolytic activities of members of the matrix metalloproteinase (MMP) family. More specifically, MMP-9 and MT1-MMP directly regulate angiogenesis, while several studies indicate a role for MMP-2 as well.
Gregg B. Fields, Gregg B. Fields
doaj +1 more source
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future [PDF]
, 2019 Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies.
Corson, Timothy W., Park, Bomina
core +1 more source
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis [PDF]
, 2014 We have shown in vitro that thyroid hormones (THs) regulate the balance between proliferation and apoptosis of T lymphoma cells. The effects of THs on tumor development have been studied, but the results are still controversial.
Barreiro Arcos, María Laura +10 more
core +1 more source
Frontiers in Oncology, 2022 Lung cancer growth is dependent on angiogenesis. In recent years, angiogenesis inhibitors have attracted more and more attention as potential lung cancer treatments. Current anti-angiogenic drugs targeting VEGF or receptor tyrosine kinases mainly inhibit
Yingying Li +5 more
doaj +1 more source
Angiogenesis, Thrombospondin-1 and Cervical Carcinogenesis
Taiwanese Journal of Obstetrics & Gynecology, 2005 Angiogenesis, the growth of new vessels from existing vasculature, plays an essential role in tumor development. The process involves interaction among cancer cells, endothelial cells, and components of the extracellular matrix, and is regulated by the ...
Ming-Ping Wu, Cheng-Yang Chou
doaj +1 more source
Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum [PDF]
, 2003 The matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), may mediate the dramatic structural and functional changes in the corpus luteum (CL) over the course of its life span.
Moses, Marsha A. +2 more
core +3 more sources
Angiogenesis at the Interface between Basic and Clinical Research
The International Journal of Biological Markers, 1999 The field of antiangiogenesis has shown a remarkably rapid evolution from the discovery at the bench to translation into the clinic. Currently a wide variety of compounds are in clinical trial as inhibitors of angiogenesis, and new compounds are being ...
A. Albini, D. Noonan, L. Santi
doaj +1 more source
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]
, 2019 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F +14 more
core +1 more source